FDA Investigator Sherri N Rohlf, MD
Sherri N Rohlf, MD has inspections in 11 countries as of 02 May 2024. Sherri N Rohlf, MD has collaborated with a combined 3538 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
157
Last Inspection Date:
02 May 2024
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America,
Poland,
Belgium,
Germany,
Japan,
France,
India,
Canada,
Bulgaria,
Australia
Co-Investigator(s):
Aaron J Poloni,
Adam S Freeman,
Alan P Kurtzberg,
Alexander M Kay,
Allan P Kurtzberg,
Allen F Hall,
Amanda E Lewin, PhD,
Amber M Howell,
Andersoneric,
Angela Shepas,
Anh Trinh T Nguyen,
Anita Narula, PhD,
Anthony E Keller, RPh,
Armando Chavez, MS,
Ashleigh P Barkans,
Astrida B Mattson,
Barbara J Rincon,
Barbara Janine Breithaupt,
Beau R Lamb,
Betsy C Galliher,
Bonita S Chester,
Brenda L Reihing,
Brenda L Reiling,
Britton C Walker,
Bryan Baker,
Calvin K Cook,
Carl A Anderson,
Carla J Lundi,
Carla V Jordan,
CDR Thomas R Berry, PPh,
Celia L Silverstein,
Charles L Larson,
Cheryl D Mccall,
Christina D Mello,
Christina L Norton,
Christine I Shaw,
Christine M Parmentier,
Christopher S Genther,
Connie P Rezendes,
Courtney R Bratina,
Craig T Rybus,
Crystal A Harlan,
Cynthia L Gorveatt,
Dan G Eisenbrey,
David R Heiar,
Dawn E Barkans,
Deborah A Nebenzahl,
Deborah A Nebnzahl,
Dennis G Kawabata,
Devon M Shoop,
Diane C Thibodeau,
Diane Cvan Leeuwen,
Dien N Nguyen,
Dirk L Lincoln,
Donald B Mckechnie,
Douglas A Campbell,
Durell L Giles,
Dustin R Abaonza,
Elizabeth S Howell,
Eric L Scott,
Eric M Mueller, PharmD,
Felix Maldonado,
Francis J Eng,
Gajendiran Mahadevan, PhD,
Gary L Zaharek,
Gloria J Baca, MS,
Graham N Giesen,
Greg K Keshishyan,
Harmon M Blanch,
Heika R Tait,
Herminio C Francisco,
Hugh Grimoldby,
Humberto Z Gomez,
Ian J Thomson,
James C Henry,
James D Hildreth,
James R Fleckenstein,
James R Montero,
James S Cartwright,
James W Whitney,
Jane M Kreis,
Janet Pulver,
Jeanne M Weishaar,
Jeffrey J Leclair,
Jenn W Sellers,
Jessica L Kocian,
Joan T Briones,
Jocelyn E Massey,
Jocelyn T Ramos,
Joel D Martinez,
John E Emmert,
John S Hartford,
John W Banks,
Jonathan T Little,
Joseph A Seitz,
Julian C Hanson,
Kara A Scheibner, PhD,
Kathryn A Krentz,
Katlin N Stubbs,
Kenneth A Miles,
Kent A Conforti,
Kevin A Gonzalez,
Kevin P Foley,
Kimberly Lewandowski Walker,
Kirstida Patel,
Kirtida Patel,
Kurt M Hafer,
Lauren E Swantko,
Leonard H Lavi,
Linda S Leja,
Linh Tu,
Lisa K Capron,
Lori J Silverstein,
Lorna F Jones,
M Patriciaurphy Murphy,
Mai Hang,
Maira P Brading,
Marc R Dickens,
Maria Pkelly Doggett, MBA,
Marijo B Kambere, PhD,
Mark C Saale,
Mark E Imsland,
Mark W Babbitt,
Marlo Ianm Alintanahin,
Mary Ewilkerson Brinsko,
Mary R Hole,
Maya M Davis,
Melkamu Getie Kebtie, PhD,
Mendoza O Wallace,
Michael D Garcia,
Michael J Lackey,
Michelle J Hines,
Michelle M Noe,
Michelle Rfrazier Jessen, PhD,
Mohsen Rajabi Abhari, FDA,
Nancy A Saxenian Emmons,
Nancy E Byerly,
Nancy E Doyle,
Nathan R Moon,
Neali H Lucas,
Nealie C Newberger,
Neil J Traaen,
Neira Acevedo Ramos,
Paul F Rader,
Paul L Yeh,
Paul M Kawamoto,
Paul R Whitby,
Peter T Regan,
Phal K Chhun,
Philip E Ake,
Philippe A Cornet,
Phillip M Pontikos,
Raffi B Papazian,
Rebecca T Davis,
Richmond K Yip,
Robert D Tollefsen,
Robert S Sweeton,
Roger F Zabinski,
Ronald E Gill,
Ruben C Ayala, PharmD,
S Lori Brown, PhD MPH,
Sandra S Saniga,
Savini,
Scott A Nabe,
Shannon J Hall,
Shaquenta Y Perkins,
Sharon I Gundersen,
Shelley H Beausoleil,
Sheri N Rohlf,
Sherri N Rohif,
Simone E Pitts,
Stanley B Eugene, BS, BME,
State Agency,
Stephen R Souza,
Sunitha K Rajaram, PhD,
Sunny R Muir,
Susanne M Richardson, MSc RAC ELS,
Suyang Qin,
Tawny L Colling,
Teena H Aiken,
Thao T Kwan,
Thea C Grome,
Thomas R Beilke,
Timothy C Grome,
Timothy P Lafave,
Tracy K Li,
Vanessa Y Gelsey, PhD,
Vanessa Y Jacobs,
Veronica Bush,
Veronica L Bush,
Victor A Meo,
Victoria M Daddeo,
Vining,
Wayne T Smith,
William J Foust,
Xiaojun Yan,
Yumi J Hiramine,
Yvette E Guillermo,
Zachary P Wachlarowicz
Sherri N Rohlf, MD's Documents
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more